Hector Dicarlo, MD
Family Medicine · Fort Lauderdale, FLNPI 1356597785
Payments from drug & device makers
Across 319 payments — averaging $30.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Parapro, LLC$1K
- AstraZeneca$647
- Amgen$537
- AbbVie$510
- Novartis$489
- plus $4K from 32 others
What the payments were for
- Speaking & faculty fees$1,00010%
- Food & beverage$8,62589%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 74 | $2,968 |
| Parapro, LLC | 1 | $1,000 |
| AstraZeneca | 13 | $647 |
| Amgen | 26 | $537 |
| AbbVie(2 entities) | 31 | $510 |
| Novartis | 25 | $489 |
| Pfizer | 29 | $435 |
| Lilly USA, LLC | 22 | $342 |
| GSK | 10 | $279 |
| Boehringer Ingelheim | 3 | $279 |
| Esperion Therapeutics, Inc. | 11 | $269 |
| Teva Pharmaceuticals USA, Inc. | 8 | $244 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $240 |
| Biotronik Inc. | 3 | $196 |
| Biohaven Pharmaceuticals, Inc. | 7 | $195 |
| Genentech USA, Inc. | 1 | $141 |
| Novo Nordisk | 7 | $130 |
| Astellas Pharma US Inc | 5 | $122 |
| Exact Sciences | 4 | $98 |
| Abiomed | 4 | $88 |
| Idorsia Pharmaceuticals US Inc | 3 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Johnson & Johnson | 3 | $42 |
| Eisai Inc. | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Bard Peripheral Vascular, Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Dexcom, Inc. | 1 | $24 |
| Bayer | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Dermira, Inc. | 1 | $19 |
| Gilead | 1 | $18 |
| Cipher Pharmaceuticals US LLC | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
| Smith+Nephew | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Lucid Diagnostics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Natroba$1,000
- Proclaim IPG$748
- JARDIANCE$250
- Prodigy Family of SCS IPGs$162
- Actemra$141
- AJOVY$125
- NURTEC ODT$125
- FARXIGA$125
- BREZTRI$125
- Repatha$125
- ENTRESTO$122
- BEVESPI AEROSPHERE$115
- NEXLIZET$110
- NEXLETOL$110
- Edora 8 DR-T$103
- BioMonitor$103
How this compares
$9,676 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 371 | $154,989 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $59,010 |
| TrulicityDulaglutide | 52 | $57,912 |
| OzempicSemaglutide | 59 | $55,041 |
| JardianceEmpagliflozin | 81 | $43,698 |
| MounjaroTirzepatide | 37 | $38,917 |
| TradjentaLinagliptin | 66 | $35,570 |
| XifaxanRifaximin | 19 | $26,183 |
| ProcritEpoetin Alfa | 34 | $24,538 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $24,224 |
| XareltoRivaroxaban | 20 | $22,995 |
| JanuviaSitagliptin Phosphate | 46 | $20,767 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $20,566 |
| FarxigaDapagliflozin Propanediol | 23 | $17,044 |
| LinzessLinaclotide | 21 | $16,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Retacrit | $435 | $159,317395 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $342 | $96,82989 claims |
| Boehringer IngelheimJardiance, Tradjenta | $279 | $79,269147 claims |
| Novo NordiskOzempic | $130 | $55,04159 claims |
| Johnson & JohnsonProcrit, Xarelto | $42 | $47,53354 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $279 | $29,80444 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $240 | $26,18319 claims |
| AbbVieLinzess, Synthroid | $510 | $20,22946 claims |
| AstraZenecaFarxiga | $647 | $17,04423 claims |
| Astellas Pharma US IncMyrbetriq | $122 | $15,87616 claims |
| NovartisEntresto | $489 | $14,92229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Fort Lauderdale
- David MishkinFort Lauderdale$4.3M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.